ntrolledtrialofadultsinMexico. Vaccine 29,7826–7834(2011). 10.1128/JVI.01693-18(2019).
emic influenza A (H1N1) 2009 vaccine in a blinded, randomized, placebo- implicationforpotencytestingandimmuneproce
pez-Macías,C.etal.Safetyandimmunogenicityofavirus-likeparticlepan- 72. An, Y. et al. N-glycosylation of seasonal influen
fluenza-Vaccinology-Report.pdf.AccessedAugust2021. glycansinviralevolutionandvaccinedesign. Sci.T
bamawhitehouse.archives.gov/sites/default/files/microsites/ostp/PCAST- 71. Wei,C.J.etal.Cross-neutralizationof1918and20
terprisetomeetthechallengesofpandemicinfluenza.Availableathttps:// influenzavaccine:evidencefromamousemodel. J.
eport to the president on reengeneering the influenza vaccine production 70. Babiuk,S.etal.AggregatecontentinfluencestheT
7,33(2020). (2002).
hen,J.R.etal.Betterinfluenzavaccines:anindustryperspective. J.Biomed.Sci. passive surveillance, Canada 2001-2002. Can. Com
um.VaccinImmunother. 11,1209–1222(2015). 69. Choudhri,Y.&Walop,W.Influenzavaccine-associat
iang, K. et al. Progress on adenovirus-vectored universal influenza vaccines. sonsinCanada. Can.Commun.Dis.Rep. 31,217–22
pingthenextgenerationofinfluenzavaccines. Vaccines 8,574(2020). vaccination:reviewofpost-marketing surveillance
yedahmed, E. E. etal.Adenoviral vector-based vaccine platforms for devel- 68. PublicHealthAgencyofCanada.Oculo-respiratorys
ccine. PLoSONE 7,e33428–e33428(2012). 10.3390/vaccines6020031(2018).
ogenicityandprotectionconferredwithanadenovirus-basedH5N1influenza virus and within vaccines using electron microsco
andey,A.etal.Impactofpreexistingadenovirusvectorimmunityonimmu- 67. Gallagher, J. R. et al. Characterization of hemaggl
28–8038(2018). tionofinfluenzavirusvaccine. Hum.VaccinesImmun
erived virus-like particles bearing influenza hemagglutinin. Vaccine 36, 66. Tay,T.etal.Investigationintoalternativetestingme
on, S. Y. et al. Characterization of the innate stimulatory capacity of plant- dependentantibodyresponsesinhumans. NPJVac
91–1503(2020). unit vaccines in elicitation of influenza-specific C
ults (>/=65 years): two multicentre, randomised phase 3 trials. Lancet 396, 65. Richards,K.A.etal.RecombinantHA-basedvaccin
valent, virus-like particle influenza vaccine in adults (18-64 years) and older 8,99(2020).
ard,B.J.etal.Efficacy,immunogenicity,andsafetyofaplant-derived,quad- neutralizingantibodiesagainststructurallydistinctd
to49and>/=50yearsoldadults. PLoSONE 14,e0216533(2019). 64. Portnoff,A.D.etal.Influenzahemagglutininnanop
eparticleinfluenzavaccinecandidate-tworandomizedPhaseIIclinicaltrialsin hemagglutininfusionmachineryoninfluenzavirions
illet,S.etal.Immunogenicityandsafetyofaquadrivalentplant-derivedvirus 63. Benhaim, M. A. etal. Structural monitoring of a tr
munol. 168,72–87(2016). allinfluenzaAsubtypes. Cell 166,596–608(2016).
duces cross-reactive antibody and T cell response in healthy adults. Clin. 62. Kallewaard,N.L.etal.Structureandfunctionanalysi
illet,S.etal.Aplant-derivedquadrivalentviruslikeparticleinfluenzavaccine epitope. Science 324,246–251(2009).
ghtagainstCOVID-19? Vaccines 8,183(2020). 61. Ekiert, D. C. et al. Antibody recognition of a highl
osales-Mendoza,S.etal.Whatdoesplant-basedvaccinetechnologyoffertothe differentinfluenzavaccineplatformsinhumans. Na
pressedin Escherichiacoli. Gene 21,273–284(1983). 60. Khurana,S.etal.Repeatvaccinationreducesantibo
avis, A. R. et al. Immune response to human influenza virus hemagglutinin e3000139(2019).
acteria. ActaBiochimPol. 61,561–572(2014). separation of hemagglutinin receptor-binding he
czynska, V.Influenzavirus hemagglutinin asavaccine antigen produced in 59. Turner,H.L.etal.Potentanti-influenzaH7human
roducedin Escherichiacoli. PLoSONE 5,e11694(2010). (2015).
guilar-Yanez, J. M. et al. An influenza A/H1N1/2009 hemagglutinin vaccine broadly cross-reactive antibodies. Curr. Top. Micro
roteins. OpenForumInfect.Dis. 3,ofw015(2016). 58. Lee,P.S.&Wilson,I.A.Structuralcharacterizationof
asonal flu vaccine comprising recombinant hemagglutinin-flagellin fusion (1983).
ssey, L. et al. Phase 1 safety and immunogenicity study of a quadrivalent hemagglutininmoleculeofH3influenzavirusatacid
NE 3,e2257(2008). 57. Webster,R.G.,Brown,L.E.&Jackson,D.C.Chang
acterial expression: a solution to global pandemic and seasonal needs. PLoS insectandmammaliancells. Curr.Opin.Biotechnol.
ng,L.etal.Efficaciousrecombinantinfluenzavaccinesproducedbyhighyield 56. Kost,T.A.&Condreay,J.P.Recombinantbaculoviru
60-7917.Es.2017.22.13.30494(2017). revealsstructuralpolymorphisms. Clin.Vaccin.Imm
bles = European communicable disease bulletin 22, https://doi.org/10.2807/ hemagglutinin complexes by cryo-electron micro
siontoreality.Eurosurveillance:bulletinEuropeensurlesmaladiestransmis- 55. McCraw,D.M.,Gallagher,J.R.&Harris,A.K.Charact
u,Y.&McCauley,J.GISAID:Globalinitiativeonsharingallinfluenzadata-from perspective. AnnuRev.Biophys. 47,153–173(2018).
7–171(2017). 54. Boonstra, S. et al. Hemagglutinin-mediated mem
fectiveness-UnitedStates,February2017. MMWRMorb.Mortal.WklyRep. 66, 406–430(2015).
annery, B. et al. Interim estimates of 2016-17 seasonal influenza vaccine enza: the role of the haemagglutinin cleavage sit
atlAcad.Sci.USA 114,12578–12583(2017). 53. Luczo,J.M.etal.MolecularpathogenesisofH5hi
ataltersbindingofantibodieselicitedbyegg-adaptedvaccinestrains. Proc. 95,409–417(1998).
ost,S.J.etal.ContemporaryH3N2influenzaviruseshaveaglycosylationsite minantofinfluenzapathogenicityandtheoriginof
rculatingviruses. PLoSONE 9,e92153(2014). 52. Chen,J.etal.Structureofthehemagglutininprec
ith mutation in the egg-adapted H3N2 vaccine strain not antigenic drift in (1992).PMC556715.
owronski,D.M.etal.Low2012-13influenzavaccineeffectivenessassociated siteisactivatedbyfurin,asubtilisin-likeendoprote
g-adaptedvaccinestrain. Nat.Med. 22,1465–1469(2016). 51. Stieneke-Gröber,A.etal.Influenzavirushemaggluti
aymond,D.D.etal.Influenzaimmunizationelicitsantibodiesspecificforan laughingmatter. Proc.NatlAcad.Sci.USA 95,9713–
lls. J.Invertebr.Pathol. 107,S31–S41(2011). 50. Taubenberger, J.K.Influenzavirus hemagglutinin
ox,M.M.&Hashimoto,Y.Afasttrackinfluenzavirusvaccineproducedininsect sed19April2021.
0,702–714(2015). drug-products/applications-submissions/register-inn
anufacturingplatformforviralvaccinesandgenetherapyvectors. Biotechnol.J. from https://www.canada.ca/en/health-canada/ser
lberbaum, R. S. The baculovirus expression vector system: a commercial 49. HealthCanada.RegisterofInnovativeDrugs[Upda
ed. 121,S22–S27(2008). February2021.
uction,distribution,supply,anddemand–whatitmeansfortheprovider. Am.J. assessment-report/supemtek-epar-public-assessment-
renstein,W.A.&Schaffner,W.Lessonslearned:roleofinfluenzavaccinepro- EMEA/H/C/005159/0000. Available at https://www.e
lacebo-controlledphaseItrial. Nat.Med. 27,106–114(2021). 48. European Medicines Agency. Assessment report.
ccine approach induces broad and long-lasting immunity in a randomized, 2021.
achbagauer,R.etal.Achimerichemagglutinin-baseduniversalinfluenzavirus azureedge.net/media/documents/VAC_infl_publ_rpt_
ccine:differentapproachesforonegoal. Virol.J. 15,17(2018). 47. Influenza vaccine strategies for broad global acce
utto, G. A., Kirchenbaum, G. A. & Ross, T. M. Towards a universal influenza particles. ExpertRev.Vaccines 12,225–236(2013).
018). 46. Fernandes,F.etal.Insectcellsasaproductionpl
efinedbyavaccine-inducedantibody. Proc.NatlAcad.Sci.USA 115,168–173 ticlevaccine. Biopharm.Int 23Suppl10,26–34(20